| Names | |
|---|---|
| Preferred IUPAC name | sodium 2-[(2,6-dichlorophenyl)amino]phenylacetate |
| Other names | Flector Patch Diclofenac Topical Patch Diclofenac Epolamine Patch Voltaren Patch |
| Pronunciation | /daɪˌkloʊ.fəˈnæk ˈsoʊ.di.əm pætʃ/ |
| Identifiers | |
| CAS Number | 15307-79-6 |
| 3D model (JSmol) | `3D model (JSmol)` string for **Diclofenac Sodium**: ``` C1=CC=C(C=C1)C(=O)N(C2=CC=CC=C2Cl)C3=CC=CC=C3Cl.[Na+] ``` This is the **SMILES** string for Diclofenac sodium, which can be visualized in JSmol-enabled software for its 3D structure. |
| Beilstein Reference | 3959141 |
| ChEBI | CHEBI:76264 |
| ChEMBL | CHEMBL1201262 |
| ChemSpider | 7001 |
| DrugBank | DB00586 |
| ECHA InfoCard | ewc-0011875861-49-000002 |
| EC Number | 52047 |
| Gmelin Reference | Gmelin Reference: 83255 |
| KEGG | D08117 |
| MeSH | Diclofenac; Anti-Inflammatory Agents, Non-Steroidal; Drug Delivery Systems; Transdermal Patch |
| PubChem CID | 57469 |
| RTECS number | HE1773500 |
| UNII | 3V9QT8TU8E |
| UN number | UN3248 |
| CompTox Dashboard (EPA) | DTXSID8022856 |
| Properties | |
| Chemical formula | C14H10Cl2NNaO2 |
| Molar mass | 318.13 g/mol |
| Appearance | Light brown to brown adhesive patch |
| Odor | Odorless |
| Density | 0.87 g/cm³ |
| Solubility in water | Freely soluble in water |
| log P | 4.51 |
| Acidity (pKa) | 4.0 |
| Basicity (pKb) | pKb: 11.86 |
| Dipole moment | 3.45 D |
| Pharmacology | |
| ATC code | M02AA15 |
| Hazards | |
| Main hazards | May cause skin irritation, allergic reactions, and increased risk of gastrointestinal, cardiovascular, and renal adverse effects. |
| GHS labelling | GHS07, Warning, Causes skin irritation. Causes serious eye irritation. |
| Pictograms | eye irritation, skin irritation, asthma, pregnancy, breastfeeding, child, elderly, driving, alcohol, kidney, liver, stomach, heart |
| Signal word | Warning |
| Hazard statements | Harmful if swallowed. Causes skin irritation. Causes serious eye irritation. |
| Precautionary statements | Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. For external use only. Do not use on damaged or broken skin. Stop use and ask a doctor if rash, irritation, or excessive skin reaction develops. |
| NFPA 704 (fire diamond) | 1-1-0 |
| Lethal dose or concentration | LD50 (rat, oral): 55 mg/kg |
| LD50 (median dose) | LD50 (median dose): Rats (oral) 55 mg/kg |
| PEL (Permissible) | 10 mg/patch |
| REL (Recommended) | 140 mg/day |
| IDLH (Immediate danger) | Not listed. |
| Related compounds | |
| Related compounds | Aceclofenac Bromfenac Etodolac Indomethacin Ketoprofen Nabumetone Sulindac |
| Product Identification | Details |
|---|---|
| Product Name | Diclofenac Sodium Patch |
| IUPAC Name | Sodium 2-[(2,6-dichlorophenyl)amino]phenylacetate (incorporated onto adhesive patch matrix for topical delivery) |
| Chemical Formula | C14H10Cl2NNaO2 (active component) |
| Synonyms & Trade Names | Diclofenac sodium external patch, NSAID patch, topical diclofenac patch. Commercially, trade names and labeling formats can differ regionally. Manufacturer formulas often adapt matrix type, release profile, and excipient content to meet customer-specific regulatory and clinical criteria. |
| HS Code & Customs Classification | HS Code assignment commonly follows 3004.90 for finished pharmaceutical preparations. Import and export documents may require clarification whether a patch falls under "medicaments put up in measured doses" or "transdermal delivery systems" depending on local customs practices. Customs authorities review documentation for finished dosage form registration status and declared use before final confirmation. Classification can shift if supplied as bulk matrix or API-in-contact material rather than finished, pack-ready patch. |
Diclofenac sodium patches require consistently pure sodium diclofenac API conforming to pharmacopoeial standards since topical usage increases sensitivity to impurities and particle morphology. Raw material selection focuses on flowability, minimal residual solvents, and defined polymorphic forms for integration into the matrix. Industrial production emphasizes matrix compatibility, solvent system optimization, and control of water activity to preserve adhesive integrity and uniform API distribution. Batch consistency hinges on in-process viscosity, coating uniformity, and drying profiles. Each customer may specify acceptance criteria including adhesive type (hydrogel, acrylic, rubber-based), release liner architecture, and maximum extractables/leachables profiles. Manufacturing routes and key control points are designed to minimize incorporation of particles, unreacted precursors, and degradation products.
Physical characteristics, including adhesive tack, patch thickness, and API homogeneity, can vary depending on intended medical application, batch scale, and downstream packaging. For pharmaceutical-grade patches, regulatory filings (e.g. US FDA, EU EMA) demand documentary evidence of lot-wise homogeneity, endotoxin control, and residual solvent profile. Stability and shelf life tie directly to primary excipient purity, water content adjustment, and choice of barrier film. Most process deviations—such as API agglomeration or incomplete solvent removal—present in the finished patch as visible non-uniformity or content variability, flagged by in-line inspection and physical testing protocols. Release criteria are set by technical negotiation with customers and local authorities, with reference to clinical performance data and user safety expectations.
Sources of impurities originate from both API synthesis and downstream integration. Polymorph or amorphous content in the API, trace amounts of synthesis byproducts, and minor adhesive residuals require lot-by-lot monitoring. Patches with incomplete solvent removal can fail content uniformity or skin irritation thresholds. Ongoing batch validation studies focus on cumulative extractable and leachable content, visual external assessment, and controlled release rates over labelled expiry period. Process control includes in-line moisture checks, adhesion peel strength measurement, particle screening, and XRF or HPLC for homogeneity. Final quality release depends on customer-specified pharmaco-technical performance and regulatory compliance evidence for each market.
Diclofenac sodium patch incorporates an API embedded within a polymeric adhesive matrix. The physical form typically appears as a flexible, translucent to opaque sheet depending on matrix and backing film selection. The odor remains faint or non-detectable due to encapsulation. Melting and boiling point measurements for the finished patch are not practical, as patches are designed for topical stability instead of melt processing.
Final density and feel rely on supplier-grade adhesive and film. Melting point of pure diclofenac sodium exists in raw material lot certificates but loses direct meaning inside composite patch. Patches should avoid excessive stickiness or brittleness; these qualities reflect polymer choice and residual solvent levels from manufacturing, which are tightly controlled by QC to meet customer application standards.
Stability of diclofenac sodium within the adhesive system is assessed via forced degradation and real-time aging studies. Reactive impurities especially hydrolysis and oxidation byproducts require close monitoring due to risks of discoloration or odor in the finished patch. Different grades include matrix stabilizers or antioxidants, which adjust the stability profile. Key observation: exposure to strong acids, oxidizing agents, or UV initiates degradation, prompting specific requirements on patch formulation to suppress such reactions.
Raw diclofenac sodium exhibits water solubility; in matrix formulation, it is dispersed or partially dissolved depending on adhesive system. For manufacturing, uniform dissolution in volatile solvents or co-solvents supports even drug distribution and dose accuracy. Each batch demands solvent compatibility and post-drying dissolution checks to verify no crystallized drug exists on the finished lamina.
Batch specs differ between medical and OTC patch grades, including active content uniformity, patch thickness, adhesion force, and residual solvent limits. High-load prescription patches emphasize API accuracy and low impurity profile. Non-prescription grades may permit broader tolerances for adhesive strength. Final specs follow internal batch release criteria and, if relevant, the pharmacopoeial or local registration requirements.
Observed impurities derive from diclofenac sodium synthesis (e.g. organic residuals, degradation products) or are introduced during the patch coating process (e.g., isomeric species or byproducts from UV curing). Typical industrial practice involves LC-based profiling and assignment of limits aligned with regulatory and internal guidelines tailored to patch dose and dermal exposure.
Test methods prioritize HPLC for purity and content assay, mechanical peel tests for adhesive force, and finished patch evaluations for dose uniformity per patch area. Reference standards are drawn from recognized pharmacopeia where available, modified by internal validation according to patch format and matrix technology.
API sourced from GMP-certified manufacturers, with emphasis on recent COA verified by retesting. Matrix polymers, release liners, and backing films sourced with focus on biocompatibility and migration profiles. Supply chain for medical patch components undergoes close qualification and audit. Each lot is tracked from intake through manufacturing.
In-house synthesis, if performed, typically begins from orthodichloroaniline and proceeds via acylation and salt formation. Commercial patch production rarely synthesizes the API on-site, but relies on validated third-party supply. The key manufacturing challenge is not API synthesis, but API-matrix integration. API is suspended or dissolved with adhesive in solvent, coated onto film substrate, dried under controlled thermal profile, and covered with a release liner.
Primary control points: solvent evaporation rates, coating uniformity, and residual solvent testing. Exhaustive inline QC ensures no hot spots of excessive API or residuals. Impurities are addressed during bulk API reception and during solution prep by filtration or adsorption if needed. Patches with non-uniformity result in batch rejection. Finished sheets cut into the final dose units only after complete batch analytics.
Release requires compliance against agreed specifications: content uniformity, mechanical performance, absence of critical degradants. Random sampling for each lot checks for content, peel force, and shelf aging stability. Each batch must trace back across the entire manufacturing history for raw material, process conditions, and final test outcome.
API molecule may undergo hydrolysis, oxidation, and photolytic transformation, especially during dissolved phase or storage. Reactive exposure routinely controlled by matrix stabilizer selection and use of opaque or UV-resistant packaging.
Manufacturing employs standard solvent-coating at moderate temperatures dictated by adhesive system limits. No strong catalysts or unusual reaction conditions are used; critical parameters include residual solvent minimization, prevention of localized overheating, and maintaining inert environment during high-shear mixing if required.
Further chemical modification of the patch system typically falls outside standard production scope. Research groups may adapt the matrix for co-delivery with skin permeation enhancers or add layers for tailored release, but active pharmaceutical ingredient remains unaltered in mainstream patch production. Downstream integration focuses on compatibility with secondary packaging, not on molecular derivatization.
Recommended storage avoids elevated temperature, direct sunlight, and excessive humidity due to risk of matrix flow, adhesive breakdown, and API degradation. Gas-impermeable, light-protective foil pouches are standard for primary packaging. For multi-country supply, local storage guidance aligns with observed regional climate impact on patch performance.
Finished product relies on packaging films with documented chemical non-reactivity towards diclofenac, its impurities, and excipients. Compatibility testing is performed for all new liner, release foil, or pouch materials prior to commercial switch.
Shelf life determination uses both accelerated and long-term conditions, confirmed by retained content, adhesion properties, and visual inspection. Degraded patches may show visible color shift, odor, or separation of adhesive from backing. Shelf life values depend on formulation and storage—manufacturers assign conservative shelf life until post-market stability supports extension.
Diclofenac sodium API aligns with regulatory GHS hazard classification for irritation and possible sensitization on dermal exposure. The finished patch, as a matrix system, poses less risk but requires handling precautions during bulk manufacture and cutting, particularly for workers in direct contact with concentrated forms.
Manufacturing staff adhere to mandatory PPE policies including nitrile gloves and goggles during coating and cutting. Dust and airborne residue are minimized by wet process steps and local extraction. Open handling of raw API employs exposure-control drumming with monitored air/particle levels.
API toxicity and sensitization risk guide allowable skin-contact limits and restrict impurities to within pharmacopoeial or internally justified thresholds for dermal exposure. Toxicological assessment also applies to matrix excipients and adhesives as required by medical product guidelines.
Specific national exposure limits for diclofenac sodium apply to powder and dust stage in manufacturing; engineering controls and local exhaust are primary measures. Finished patches, outside of rare allergic or misuse incidents, feature low occupational risk. All operations are led by SOPs covering accidental exposure, hazardous waste, and spill response.
Diclofenac Sodium Patch production hinges on controlled batch manufacturing with main bottlenecks arising from API sourcing, backing/release liner materials, and GMP cleanroom utilization. Output rates shift according to customer-specified batch sizes, grade, and order sequencing. For hospital supply and regulated market deliveries, lead times run longer due to extended QC and release batch record review. For commercial bulk, especially wholesale grades, slotting is typically more flexible, but allocation may fluctuate during global shortages of pharmaceutical excipients or packaging film.
Lead time can range from 4 to over 12 weeks, depending on grade (regulated/hospital/R&D) and packaging requirements. Custom branding, serialization, and serialization-compliant packaging create longer cycle times. MOQ is tiered: clinical supply and research grades carry lower starting points, while multi-market, branded orders invoke higher thresholds for cost effectiveness.
Standard patch packaging includes individual sachets, multi-pouch cartons with desiccant, or bulk foiled rolls for secondary assembly. Customization options, such as child-resistant pouches, tamper-evident labeling, or serialization, are determined by both grade and end-market regulatory requirements.
Shipping involves validated cold-chain or room-temperature freight, subject to the region and product grade. Payment terms reflect customer history, order value, and currency risk. International shipments conform to INCO terms, and special handling documents (such as Certificate of Analysis, GMP Certificate) accompany regulated batches.
Direct costs cluster around API (diclofenac sodium, pharmaceutical grade), pressure-sensitive adhesive polymers, film or textile reinforcements, and release liners sourced from certified suppliers. API fluctuations track solvent and precursor pricing as well as compliance status of the original API manufacturer (EU-GMP, US-FDA, PMDA-Japan). Adhesive and film procurement is sensitive to petrochemical market shifts. Labor and utilities constitute variable but minor cost blocks for finished patches.
API price swings form the largest variable. Shortages in key chemical precursors, export restrictions, or delays in regulatory re-inspection can cause abrupt spot price changes. Packaging films and adhesives see trickle-down effects from resin price volatility and logistics interruptions. Power and environmental controls in the manufacturing plant can add localized cost surges, especially during regional energy rationing or compliance upgrades.
Grade sets the baseline price band; hospital and regulated market patches require higher input API purity (generally 99%+ on dry basis), readable certification across the supply chain, and evidence of absence of extractables/leachables in final packaging. Commercial grades, typically for non-regulated or less stringent markets, permit broader material sources, looser documentation, resulting in differentiated pricing. Batch release status (full CoA, QP documentation, serialization) and packaging compliance (FDA CFR, EU MDR, local standards) generate additional cost tiers.
Diclofenac Sodium Patch demand reflects prescription volumes for pain management, shifting with raeimbursement policies, OTC switches, and regulatory approvals. Major supply clusters concentrate in India, China, the European Union, and select US CMO facilities. Regulatory re-inspection cycles and excipient import limits in the US and EU drive periodic shortages. Seasonal demand peaks emerge during flu seasons and post-pandemic medical backlog clearance.
United States and EU markets require cGMP+ serialization and traceability; any compliance rejections at border or local site trigger expedited spot buying from alternative sources, distorting pricing. Japan maintains strict excipient traceability, typically placing higher value on advanced packaging and consistency documentation. India and China operate as primary production bases; their price sensitivity tracks local API and film feedstock access, plus regulatory certifications valid for export.
Projections suggest upward pressure on finished patch pricing; compliance tightening (serialization expansion, packaging waste management), raw material volatility (especially for EU/US GMP-grade diclofenac sodium), and continued logistics cost elevation figure as key drivers. Regional differences may widen, especially between regulatory-grade and commercial-grade supply. Data-driven forecasting based on supply chain analytics, public procurement data, and major pharmaceutical tender awards shapes outlook.
Analysis incorporates on-ground supplier intelligence, international public tender results, customs price data, and production planning records. Market price signals synthesize feedback from major hospital purchasing groups, distribution partners, and direct regulatory filings. Volatility metrics draw on raw material indices and global trade flow reporting.
2023–2024 saw increased regulatory inspections affecting API supply from key Indian and Chinese plants. EU packaging legislation revision has pushed for eco-friendlier backing materials and compliance with full traceability from backing to sachet. Major hospital tenders in Western Europe and East Asia have adopted stricter batch documentation and serialization mandates.
New standards tie serialization to secondary packaging and strengthen requirements for allergen-free components. GMP 2024 amendments require expanded environmental monitoring in production, raising operational and material qualification scrutiny, especially for exporters shipping to US and EU.
Manufacturers have overhauled supplier qualification routines, diversified API sources for supply resilience, and increased investment in real-time batch monitoring. Production scheduling now prioritizes critical regulatory market orders to pre-empt trade or inspection delays. Packaging redesign projects target full compliance with pending environmental and recyclability rules for 2026 and beyond.
Diclofenac sodium patch is produced to support a range of topical pharmaceutical and medical use-cases, mostly for pain management, inflammation reduction, and symptomatic relief in musculoskeletal disorders. Our manufacturing extends to pharmaceutical preparations (OTC medicated plasters, prescription patches) and veterinary healthcare segments.
| Application | Grade | Key Parameters by Application |
|---|---|---|
| Human Prescription Use | Pharma Grade (EP/USP/BP) | Regulatory compliance, residual solvent profile, endotoxin limits, extractable metals, detailed impurity profile, bioburden management. |
| OTC/Consumer Use | Pharma Grade (EP/USP/BP, occasionally customized) | Consistency in release, microbiological purity, allergen and sensitizer screenings per region, compatibility with excipients, migration behavior in patch matrix. |
| Veterinary Use | Veterinary Compliant Grade | May allow higher impurity/trace solvent thresholds, typically region-specific compliance, formulation behavior in animal skin, batch-to-batch consistency. |
For all grades, critical factors include particle size distribution (affecting adhesion and skin penetration), residual solvent content (especially in solvent-casting processes), moisture control, and trace organics management. Patches often require low water content for stable drug-in-matrix systems, and sensitive application sites call for tight control of bioburden and heavy metals.
Physical form may be customized (micronized, technical powder, pre-dispersed) based on downstream handling. Certain customers request pre-screened grades for specific patch fabrication methods (e.g., hot-melt vs. solution-casting).
Determine the intended end-use: prescription, OTC, or veterinary sector. Clinical administration routes and target population (adult, pediatric, animal species) impact the required grade and compliance strategy.
Pin down the required pharmacopeial monograph (such as USP, EP, BP), as well as national regulations. For multinational launches, harmonize to the strictest market requirements. Assess expectations about documentation depth, traceability, and supplier certifications.
Specify limit requirements for known impurities and residual solvents. Many large-scale patch customers request certificates of analysis with impurity mapping per batch. Consider requirements for allergen testing and, if relevant, restrictions on animal-derived processing aids.
Higher-volume buyers may benefit from larger batch runs, supporting tighter within-batch property coverage. Smaller users often align with standard pack sizes to minimize revalidation costs. For price-sensitive sectors (veterinary, OTC), it helps to discuss acceptable technical vs. pharma-grade tradeoffs.
Before full supply, conduct your own pilot-scale patch runs. Validate compatibility with excipients and patch backing, check for uniform release and cutability, and evaluate appearance and functional performance in your matrix. Most recurring customers require three-lot sample variation reports prior to first order approval.
At the manufacturing level, selection of pharmaceutical intermediates and excipients requires a deep audit of upstream supply purity and traceability. For Diclofenac sodium API, critical control points include solvent quality (since trace residuals may persist to final patch), and in-process particle size management, which has a direct effect on dissolution rate and patch efficacy. Moisture ingress is managed through desiccant and inert gas atmosphere in final packing.
Batch consistency is anchored by rigorous process analytical controls, including regular in-process sampling and inline monitoring. Each batch undergoes impurity profiling, with grades split according to different internal release standards depending on end-industry channel.
Decisions in route-of-synthesis (e.g., solvent system, crystallization vs. spray-drying) arise from a balance between throughput, impurity risk, and intended field of application. For human and veterinary use, risk mitigation against nitrosamines and unreacted starting materials draws significant focus, with special process steps to minimize or segregate specific impurity classes.
For technical clients, sharing batch consistency data, lifecycle impurity trends, and demonstrable process map transparency builds confidence in ongoing supply suitability. In patch formulations targeting global markets, we maintain internal batch-retention and reference standards to facilitate both customer side and regulatory re-testing needs.
Our factory’s quality management approach builds on established GMP standards applicable to topical pharmaceutical preparations. Batch traceability ties each lot directly to raw material intake, supporting continuous audit readiness. Regular third-party audits verify our documented processes for synthesis, blending, coating, and release. We maintain compliance records reflecting annual reviews and process adaptation based on regulatory updates and customer feedback. Plants carry ISO 9001 as routine, with supplementary certification (such as ISO 13485 for medical devices) for clients requesting device-grade supply chains.
Diclofenac sodium patch lines may operate under both national drug regulatory approvals (where marketed as an API-excipient combination) and medical device registration, depending on regional product status. Certificate of Analysis, Regulatory Support Files, and Drug Master Files (DMF/ASMF) are available in supported jurisdictions. Product release includes purity and assay documentation, micro limits (per pharmacopoeial monograph, where applicable), extractable content, and adhesive performance. Product-specific certification adapts to documented endpoints (e.g., European Pharmacopeia, US FDA, CFDA) according to batch release market and customer audit requirements.
Clients can expect a full technical dossier for every product batch, including process flow, raw material origin logs, and in-process control sheets. Analytical test reports reference validated HPLC/UV for content uniformity and impurity analysis, alongside adhesion and dissolution testing as defined by the product grade. Routine stability studies, microbial testing, and in-house batch records remain accessible for review during audits or upon purchaser request. Our technical team offers further support with issue investigation, root cause analysis, and CAPA documentation as required by customer quality systems.
Production scheduling works with forecast signals and contract-based supply plans. Typical lead times vary depending on grade and annual offtake volume. We limit the portfolio of supplied patch grades per line to avoid cross-contamination and support reliable output per customer contract. Seasonal or regulatory-driven fluctuations in demand are balanced via reserved equipment slots and buffer inventory. Priority is given to multinational clients running clinical or commercial campaigns with regulatory obligations. Collaboration terms—volume guarantees, pricing update cycles, packaging customizations—adapt to program scope and regulatory territory.
Raw input for the diclofenac sodium compound is sourced from pre-qualified vendors who can demonstrate analytical traceability, with batch reservation at origin. Mainline production units address varied lot sizes, supporting both validation and commercial supply. Release schedules align to client QA timelines, and process controls track impurities, blend uniformity, backing adhesiveness, and water content. Downstream, finished patches remain protected under humidity- and light-managed storage, with scheduled release sampling for key accounts ensuring supply reliability.
Sample provision reflects product development and registration priorities; research-oriented or formulation samples ship under standard agreements, while precommercial or clinical grades require technical discussions and joint definition of performance markers. Stability and reference batch data accompany all samples, supporting customer in-house analytics and confirming process alignment. Internal review teams address sample feedback, integrating corrective action to sync with downstream scale-up or pilot requirements.
We support drop-shipment, consignment inventory, VMI, and long-term rolling forecast arrangements. For partners with changing regulatory requirements, technical change notifications and co-validation efforts align with your registration timelines. Minimum order quantity, batch-size adjustments, safety stock management, and on-demand customized packaging adapt to distributor, hospital, or CMO workflows. Production site audits, ongoing quality review meetings, and direct access to manufacturing/QA subject matter experts form part of our extended technical cooperation framework, enabling real-time resolution of issues and collaborative product lifecycle management.
Research on Diclofenac Sodium Patch focuses on maximizing API bioavailability while controlling skin irritation and adhesiveness. Formulation chemists continuously adjust polymer matrix selection and penetration enhancers, seeking to improve skin absorption without raising sensitization risk. R&D teams have explored varying grade polyacrylates, pressure-sensitive adhesives, and novel permeation modifiers. Key points of attention include achieving rapid initial release, sustaining therapeutic concentrations, and maintaining patch integrity through shelf life. In industrial scale-up, deviations in raw material batches—such as molecular weight distribution of adhesive polymers—directly affect peel strength and drug release rate. This requires ongoing collaboration between formulation and analytical teams to correlate micro-scale formulation changes with clinical and physical properties.
Recent product design efforts investigate pediatric and geriatric use where oral administration is limited. Flexible patches with low residual drug levels are in demand for outpatient and home-based care. Transdermal co-delivery strategies combining diclofenac with local anesthetics or other NSAIDs enter pilot-scale trials. Manufacturing routes adapt to region-specific regulatory guidance on excipient residuals, which affects raw material sourcing and real-time cleaning verification.
Batch-to-batch uniformity for drug content remains a persistent challenge, especially with API polymorphic transitions during solvent evaporation. The industry has seen breakthroughs in continuous casting and solvent-free lamination, reducing variability in patch thickness and content. Regulatory pressure to minimize extractables and leachables led to reforms in process solvent management and real-time impurity characterization. In-process controls focus on both visual inspection for surface uniformity and analytical quantification of drug distribution. Consistency in acrylic adhesive purity, absence of plasticizer migration, and reproducible API dissolution all define product release suitability.
The diclofenac sodium patch sector expects moderate growth, driven by aging populations with chronic musculoskeletal pain and regional OTC expansion. Industrial customers request differentiated patches designed for longer wear time with reduced skin occlusion. Market direction increasingly reflects regulatory scrutiny regarding long-term safety of excipients and packaging films.
The technical focus shifts toward patch miniaturization, dose-flexible formats, and smart indicators (such as wear-time markers). Equipment upgrades move toward continuous processing and in-line Raman spectroscopy to track real-time ingredient uniformity. Fluctuations in global supply of pharmaceutical-grade adhesives have motivated secondary supplier qualification and stricter incoming material authentication.
Raw material selection now prioritizes recyclable or biodegradable substrates, free of halogenated compounds. Reduction in process solvent use, closed-loop solvent recovery, and minimal water footprint are objectives under evaluation. Sustainability audits trace excipient upstream supply chains to flag non-renewable resource use. Industrial effluent is managed through multi-step solvent reclamation and API recovery before release.
Manufacturing technical teams remain available for joint application development, troubleshooting of adhesion variability, or root cause analysis of patch performance anomalies. Customers can request expert analysis of adhesion, permeation, or chemical stability at their formulation site, not limited to standard COA checks.
On-site or remote support addresses observed differences in product performance that trace to region-specific environmental factors, such as ambient humidity or secondary packaging type. Guidance covers recommended application techniques, customized patch size or dosage format design, and review of patient acceptance studies if indicated by customer trials.
After delivery, technical service tracks customer-reported deviations, initiates root cause investigation within production or QC, and facilitates ongoing improvements. Logbooks document lot traceability, and corrective actions follow stringent change management protocols. Persistent technical queries or quality incidents trigger formal process reviews involving batch record examination, supplier feedback, and potential revalidation. Long-term partnerships include periodic technical training, regulatory update sharing, and active feedback channels for evolving product requirements.
Our production lines for Diclofenac Sodium Patch run on a consistent schedule, with well-documented processes guiding each stage from the selection of active ingredients to final lamination and packaging. We run multiple batches daily using controlled cleanrooms and maintain detailed batch records for tracking and regulatory needs. Every patch leaving our plant reflects a controlled drying profile and zero-defect adhesion on the patch matrix. The accuracy of diclofenac sodium loading receives continuous verification with in-house HPLC and content uniformity tests on representative samples for every lot.
Pharmaceutical companies incorporate Diclofenac Sodium Patch as a primary ingredient in topical NSAID portfolios. Hospital supply organizations use large-quantity contract lots to fill tenders and institutional use. Contract drug manufacturers rely on our patches for re-packaging or private label development, especially in regulated markets where reproducibility counts. Industrial buyers working in logistics, hospital systems, and pharma wholesale restock on a rolling schedule, which requires adherence to time-sensitive demand windows.
Each production batch undergoes strict verification protocols. Standard operating procedures cover everything from the in-house weighing of diclofenac sodium, coating dispersion, matrix setting, to individual weight, thickness, and content checks on random samples. Our QA team runs FTIR, dissolution, and stability tests on retention samples monthly. We avoid cross-contamination through separation of raw and final material handling, employing stainless-steel transfer systems with dedicated HVAC. Defect incidents, whether micro-tears or thickness deviations, trigger root cause analysis and corrective actions. As a manufacturer with full site ownership, we take regulatory inspections seriously and comply with all necessary GMP files and mandatory stability data for major markets.
We operate multiple heat-sealing and vacuum-wrapping stations to match global shipping demands. Finished packs, whether bulk cartons or consumer-ready units, follow a moisture-protection protocol. Every shipment leaves the plant with tamper-proof seals and traceable barcodes linked to our digital ERP. Our packaging withstands pallet stacking for air and sea freight—stress-tested during seasonal humidity spikes and temperature fluctuations. Industrial buyers receive documentation on request, including COA, batch traceability, and export compliance records.
Our technical staff supports partners through direct consultation, including custom patch size, absorption kinetics adjustment, and adhesive formula modifications unique to local regulatory or clinical requirements. We provide technical dossiers for registration, handle audit walkthroughs in case of regulatory due diligence, and work with in-house staff at client facilities to verify application hardware setup. Whenever pharmaceutical clients face solubility, physical stability, or residual solvent questions, our chemists supply data and process insight based on our own experience at scale.
Large industrial buyers need more than a unit price quote. We help partners build multi-cycle forecasts, lock in annual supply plans, and mitigate price volatility through hedging options on chemical precursors. Our business model allows for consolidated shipments that optimize customs clearance and regional distribution centers. Procurement teams receive direct visibility into batch scheduling and shipping timelines. Our plant management cycle keeps lead times steady, even during seasonal demand shifts. For manufacturers and distributors expanding their product ranges, our team offers ongoing technical support and regulatory submission assistance, reducing administrative workload.
| Aspect | Details |
|---|---|
| Batch Size (Standard) | Scalable to industrial contract quantities |
| Quality Control Tests | HPLC, FTIR, Dissolution, Adhesion, Weight |
| Packing Types | Bespoke carton sizes, retail, or hospital packs |
| Lead Times | Stable weekly output, export-compliant shipping |
| Support | Direct technical consultations, dossier provision |
With direct control of production and long-term experience serving high-volume buyers, we ensure every batch of Diclofenac Sodium Patch meets both the technical and commercial requirements set by industrial partners. Our commitment to transparency, regulatory readiness, and scalable capacity underlines our long-term relationships across pharmaceutical and institutional channels.
Manufacturing a quality Diclofenac Sodium Patch means getting familiar with how the molecule behaves from the ground up. Diclofenac is a well-established nonsteroidal anti-inflammatory drug. Once applied, the patch delivers diclofenac sodium directly through the skin to the targeted tissue. Local absorption bypasses much of the gastrointestinal tract and systemic circulation, which leads to fewer stomach-related side effects compared to oral tablets or capsules. By focusing delivery right at the source of inflammation, patients can expect efficient relief with reduced risk of unwanted systemic reactions.
Diclofenac blocks the action of cyclooxygenase enzymes—COX-1 and COX-2. These enzymes drive the production of prostaglandins, which signal pain, swelling, and inflammation in response to injury. By inhibiting prostaglandin synthesis locally, the patch interferes with the biochemical signals that cause discomfort, thereby reducing swelling and improving mobility. The rate and depth of absorption depend on formulation, excipients, and adhesive environment, so we pay close attention to the composition during production.
Clinicians and end-users consistently reach for Diclofenac Sodium Patches to address musculoskeletal issues. Based on region-specific approvals and established use, common applications include mild to moderate pain from soft tissue injuries such as sprains, strains, and bruises. Many rehabilitation professionals also apply patches for localized osteoarthritis pain—especially in the knees and hands. Acute back pain and some sports-related conditions have shown good response rates, provided the product adheres well and is used as part of a structured therapy plan.
From the manufacturing side, we continually monitor scientific literature and clinical feedback to ensure our formulation supports these uses. In practice, patients report improved daily function and activity when patches are applied early in the course of an injury. The patch offers an alternative to higher-dose oral anti-inflammatory agents, providing flexibility for those who either cannot tolerate pills or wish to minimize systemic exposure due to age, comorbidities, or polypharmacy.
Producing a consistent, medically credible transdermal patch takes more than just mixing ingredients. Stability of diclofenac sodium, even distribution in the adhesive matrix, and proper skin adhesion are all critical for performance. Our technical team invests significant resources in process validation and in-line quality control, catching any deviations early in the batch run. By maintaining strict cleanliness standards and precise environmental controls, we can prevent issues like crystallization or patch delamination.
We manufacture with patient safety in mind. It’s not just the active ingredient that counts; skin-compatible adhesives and hypoallergenic backing layers play important roles. Every adhesive matrix batch undergoes testing for biocompatibility and release profiles. For hospital and pharmacy clients, we provide detailed certificates of analysis with shipment as standard practice, illustrating the batch’s compliance on active load, uniformity, and microbial safety.
Any transdermal therapy presents specific challenges: skin irritation risk, varying absorption rates across patient populations, and potential allergies. We continually incorporate feedback from healthcare environments and update the product based on the latest safety data. In-house research focuses on improving patch wear-time and minimizing residual adhesive after removal, backing up our commitment to innovation. We consider these steps essential for strengthening the value our product delivers—directly impacting both clinical experience and patient comfort.
Managing production on an industrial scale requires alignment between machinery setup, regulatory compliance, and economic output. For our Diclofenac Sodium Patch line, the minimum order quantity reflects these underlying processes. Most batch runs, from active ingredient blending to final packaging, demand a baseline scale to allocate our resources efficiently. We set our minimum order quantity at 30,000 patches per batch. This size allows our plant to run with proper raw material input, adherence to GMP workflows, and rigorous final QC inspections. Orders below this threshold often result in unnecessary production downtime, increased operational costs, and disrupted supply chain coordination for raw materials such as pharmaceutical-grade adhesives and backing films.
Raw materials for drug-in-adhesive patches must be sourced under strict vetting, and our analytical testing processes are uncompromising. For standard Diclofenac Sodium Patch formulations, our average lead time stands at 5 to 7 weeks from order confirmation. This window covers API reservation, preparation of the adhesive mix, batch coating, cutting, and packing, followed by mandatory stability and analytical checks before release.
Demand spikes or custom modifications—such as alternative patch sizes or adjusted loading of active compound—extend that lead time by another 2 to 3 weeks. This additional time includes regulatory documentation, pilot-scale validation, and sometimes tailored secondary packaging. We prioritize transparency at every stage, so if a customer requires product for clinical trials, packaging in bulk rolls, or region-specific serialization, our technical team will outline the timeline precisely during contract review.
Raw material volatility, energy costs, and regulatory expenses all feed into our pricing. For Diclofenac Sodium Patches, our pricing structure uses a tiered model tied directly to volume. Orders meeting the minimum quantity receive our baseline unit price; as order sizes move past 100,000 units, structured discounts apply, reflecting scale economies on material procurement and batch processing. Our plant can accommodate annual contract volumes, recurring shipments, or multi-shipment scheduling; price-per-unit drops on substantial volume commitments or supply agreements that optimize line utilization and resource planning.
Customizations, stricter packaging requirements, or tailored patch assemblies—if requested—will be quoted separately. All quotes account for global GDP-compliant freight, regulatory export documentation, and, if requested, integration with customer inventory systems. We update our prices regularly to reflect shifts in API sourcing costs or any policy changes that impact the pharma export market.
Some customers approach us about reducing lead times. Based on our direct manufacturing experience, the most effective solution is forecast-based scheduling: supplying advance demand signals allows earlier raw material booking and production slot allocation, which shaves time off the standard cycle. Multi-year agreements help us manage inventories for critical inputs, buffering against market swings and securing continuity of supply.
We work closely with partners who require batch-level traceability, customized documentation for regulatory submissions, or expedited shipment channels for temperature-sensitive cargo. Our technical and logistics departments coordinate directly with customer teams—whether it involves accelerated quality release or harmonizing packaging formats with existing distribution systems. This direct approach consistently minimizes delays, maximizes accountability, and keeps procurement costs predictable over the contract period.
We’re committed to direct, long-term relationships with pharmaceutical partners, offering full transparency from first inquiry through delivery, and supporting every project with clear, experience-driven guidance. Diclofenac Sodium Patch procurement is a technical, highly regulated transaction; working manufacturer-to-customer ensures stability, efficiency, and reliability through every phase.
Managing stability and performance over time calls for thoughtful storage policies. Our manufacturing and quality control teams build these requirements into our process from day one. Each Diclofenac Sodium Patch batch leaves our plant sealed in medical-grade protective pouches. We maintain a strict climate protocol: storage spaces remain under 25°C, shielded from direct sunlight, and protected against moisture or high humidity. We pack each carton with clear symbols and printed guidance, ensuring that storage practices remain consistent from the factory floor to the end-use warehouse.
Our own shelf life studies indicate that, under recommended conditions, the standard patch maintains its intended properties for at least two years from the production date. We print the manufacturing and expiration dates on every master carton and retail box, eliminating confusion for importers and warehouse operators. For ongoing stability, our quality team periodically samples retained inventory, checks for content consistency, and tracks any deviations. Product recalls or compliance flags have never resulted from overlooked storage or dating errors.
Each country defines its regulatory boundaries. We carry and maintain certification from agencies like the US FDA, EU CE (for medical devices), and national GMP licenses. For Rut-based or sodium-diclofenac external patches, official conformity assessments include ingredient testing, leachables, strength uniformity, and adhesion performance. Our documentation process includes Certificates of Analysis, batch-by-batch traceability, and up-to-date product registration files. Our staff communicates directly with import authorities and customs brokers, answering technical and compliance queries with data files and production certificates that originate in our own facilities.
Importers and distributors want clarity on the standards behind every shipment. Our in-house compliance specialists assist with targeted reports that demonstrate ingredient content by validated HPLC, confirm the absence of banned impurities, and list our annual GMP and ISO 13485 audit results. Each box and package carries clear labeling in multiple languages, as dictated by country-specific medical device and pharmaceutical regulations. Our internal audit program reviews every detail before export documents are issued.
Climate, logistics, and documentation chain breakdowns can undermine even the best production. We design packaging to withstand temperature and humidity spikes during ocean and air freight. Our dispatch team trains every team member in how to handle irregularities, such as broken seals or evidence of leaks. When auditors demand a summary of storage qualifications, we provide real-world records from our own warehouses and field logistics partners, not boilerplate documents. We use data loggers to monitor shipping environments for critical international orders, and include those readings in compliance reports where required.
Regulatory shifts present new documentation or material requirements each year. Our regulatory affairs team maintains direct contact with key authorities, tracks updates in medical device and drug technical standards, and adapts file formats or patch composition as those standards change. We invest in continuous training for production staff and update our SOPs every time a major compliance revision lands. Our factory’s reputation with customs and health inspectors comes from diligence and clear communication, not last-minute paperwork fixes.
From secure packaging to transparent documentation and direct engagement with authorities, we build reliability into every step of the manufacturing and export process for Diclofenac Sodium Patch. Our commitment ensures that every shipment meets current global standards and delivers to importers and patients as intended.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
